1
|
Wallbach M, Vasko R, Hoffmann S, Niewold TB, Müller GA, Korsten P. Elevated procalcitonin levels in a severe lupus flare without infection. Lupus 2016; 25:1625-1626. [DOI: 10.1177/0961203316651746] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Accepted: 05/04/2016] [Indexed: 11/16/2022]
Affiliation(s)
- M Wallbach
- Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany
| | - R Vasko
- Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany
| | - S Hoffmann
- Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany
| | - T B Niewold
- Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, USA
| | - G A Müller
- Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany
| | - P Korsten
- Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany
| |
Collapse
|
2
|
Ungprasert P, Sagar V, Crowson CS, Amin S, Makol A, Ernste FC, Osborn TG, Moder KG, Niewold TB, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary VR. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus 2016; 26:240-247. [PMID: 27365370 DOI: 10.1177/0961203316657434] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) group published a new set of classification criteria for systemic lupus erythematosus (SLE). Studies applying these criteria to real-life scenarios have found either equal or greater sensitivity and equal or lower specificity to the 1997 ACR classification criteria (ACR 97). Nonetheless, there are no studies that have used the SLICC 12 criteria to investigate the incidence of lupus. We used the resource of the Rochester Epidemiology Project to identify incident SLE patients in Olmsted County, Minnesota, from 1993 to 2005, who fulfilled the ACR 97 or SLICC 12 criteria. A total of 58 patients met criteria by SLICC 12 and 44 patients met criteria by ACR 97. The adjusted incidence of 4.9 per 100,000 person-years by SLICC 12 was higher than that by ACR 97 (3.7 per 100,000 person-years, p = 0.04). The median duration from the appearance of first criterion to fulfillment of the criteria was shorter for the SLICC 12 than for ACR 97 (3.9 months vs 8.1 months). The higher incidence by SLICC 12 criteria came primarily from the ability to classify patients with renal-limited disease, the expansion of the immunologic criteria and the expansion of neurologic criteria.
Collapse
Affiliation(s)
- P Ungprasert
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - V Sagar
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - C S Crowson
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.,2 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - S Amin
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.,3 Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | - A Makol
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - F C Ernste
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - T G Osborn
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - K G Moder
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - T B Niewold
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - H Maradit-Kremers
- 3 Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.,4 Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA
| | - R Ramsey-Goldman
- 5 Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - V R Chowdhary
- 1 Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
3
|
Jin Z, Jensen MA, Dorschner JM, Vsetecka DM, Amin S, Makol A, Ernste F, Osborn T, Moder K, Chowdhary V, Niewold TB, Fan W. ID: 135: SINGLE CELL GENE EXPRESSION STUDIES IN LUPUS MONOCYTES REVEAL A UNIQUE ANTII-INFLAMMATORY NON-CLASSICAL MONOCYTE POPULATION ASSOCIATED WITH CLINICAL QUIESCENCE. J Investig Med 2016. [DOI: 10.1136/jim-2016-000120.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundOur previous studies have shown that different cell types from the same blood sample demonstrate diverse gene expression parameters. In follow up work, it seems that this diversity extends to cells of the same type from the same blood sample. In this study, we examine single cell gene expression in SLE patient monocytes and determine correlations with clinical features.MethodsCD14++CD16− classical monocytes (CLs) and CD14dimCD16+ non-classical monocytes (NCLs) from SLE patients were purified by magnetic separation. The Fluidigm single cell capture and pre-amplification system was used for single cell capture and target gene pre-amplification. Fluidigm Biomark system (Rt-PCR system) was used to quantify expression of 87 monocyte-related genes. IFN-induced genes in monocytes were identified by culturing monocytes isolated from whole blood of healthy controls with or without IFN-α. Genes significant up-regulated by IFN were identified as IFN-induced genes in current study. An individual cell IFN score was given based upon the sum of expression of IFN-induced genes.ResultsBoth CLs and NCLs demonstrated a wide range of expression of IFN-induced genes, and NCL monocytes had higher IFN scores than CL monocytes. Using unsupervised hierarchical clustering, we found four gene sets that clustered monocytes functionally. These included an IFN-induced gene set, two inflammatory gene sets, and one immunosuppressive gene set. Interestingly, we could define a large subset of NCL monocytes with upregulation of suppressive transcripts (including TGF-β and PDL1) and IFN-induced transcripts were also upregulated, while the two inflammatory gene sets were down-regulated. These cells were highly over-represented in a patient with inactive disease who was on immunosuppressants at the time of blood draw. The proportion of anti-inflammatory gene set expressing NCLs was inversely correlated with anti-dsDNA titers (rho=−0.77, p=0.0051) and positively correlated with C3 complement (rho=0.68, p=0.030) in the SLE patient group, suggesting that these cells are also associated with serological quiescence.ConclusionUsing single cell gene expression, we have identified a unique population of NCL monocytes in SLE patients with upregulation of a combination of anti-inflammatory and IFN-induced transcripts. These cells correspond with clinical and serological quiescence.
Collapse
|
4
|
Martins M, Williams AH, Comeau M, Marion M, Ziegler JT, Freedman BI, Merrill JT, Glenn SB, Kelly JA, Sivils KM, James JA, Guthridge JM, Alarcón-Riquelme ME, Bae SC, Kim JH, Kim D, Anaya JM, Boackle SA, Criswell LA, Kimberly RP, Alarcón GS, Brown EE, Vilá LM, Petri MA, Ramsey-Goldman R, Niewold TB, Tsao BP, Gilkeson GS, Kamen DL, Jacob CO, Stevens AM, Gaffney PM, Harley JB, Langefeld CD, Fesel C. Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study. Genes Immun 2015; 16:142-50. [PMID: 25569266 DOI: 10.1038/gene.2014.73] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 11/03/2014] [Accepted: 11/07/2014] [Indexed: 11/09/2022]
Abstract
A classic T-cell phenotype in systemic lupus erythematosus (SLE) is the downregulation and replacement of the CD3ζ chain that alters T-cell receptor signaling. However, genetic associations with SLE in the human CD247 locus that encodes CD3ζ are not well established and require replication in independent cohorts. Our aim was therefore to examine, localize and validate CD247-SLE association in a large multiethnic population. We typed 44 contiguous CD247 single-nucleotide polymorphisms (SNPs) in 8922 SLE patients and 8077 controls from four ethnically distinct populations. The strongest associations were found in the Asian population (11 SNPs in intron 1, 4.99 × 10(-4) < P < 4.15 × 10(-2)), where we further identified a five-marker haplotype (rs12141731-rs2949655-rs16859085-rs12144621-rs858554; G-G-A-G-A; P(hap) = 2.12 × 10(-5)) that exceeded the most associated single SNP rs858554 (minor allele frequency in controls = 13%; P = 4.99 × 10(-4), odds ratio = 1.32) in significance. Imputation and subsequent association analysis showed evidence of association (P < 0.05) at 27 additional SNPs within intron 1. Cross-ethnic meta-analysis, assuming an additive genetic model adjusted for population proportions, showed five SNPs with significant P-values (1.40 × 10(-3) < P< 3.97 × 10(-2)), with one (rs704848) remaining significant after Bonferroni correction (P(meta) = 2.66 × 10(-2)). Our study independently confirms and extends the association of SLE with CD247, which is shared by various autoimmune disorders and supports a common T-cell-mediated mechanism.
Collapse
Affiliation(s)
- M Martins
- 1] Instituto de Medicina Molecular, Lisboa, Portugal [2] Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | - A H Williams
- Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - M Comeau
- Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - M Marion
- Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - J T Ziegler
- Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - B I Freedman
- Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - J T Merrill
- Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - S B Glenn
- Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - J A Kelly
- Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - K M Sivils
- Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - J A James
- 1] Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA [2] Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - J M Guthridge
- Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - M E Alarcón-Riquelme
- 1] Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA [2] Centro de Genómica e Investigaciones Oncológicas (GENYO), Pfizer-Universidad de Granada-Junta de Andalucía, Granada, Spain
| | - S-C Bae
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea
| | - J-H Kim
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea
| | - D Kim
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea
| | - J-M Anaya
- Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogota, Colombia
| | - S A Boackle
- Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, USA
| | - L A Criswell
- Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California, San Francisco, CA, USA
| | - R P Kimberly
- Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - G S Alarcón
- Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - E E Brown
- Departments of Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - L M Vilá
- Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
| | - M A Petri
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - R Ramsey-Goldman
- Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - T B Niewold
- Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, USA
| | - B P Tsao
- Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, USA
| | - G S Gilkeson
- Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
| | - D L Kamen
- Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
| | - C O Jacob
- Department of Medicine, University of Southern California, Los Angeles, CA, USA
| | - A M Stevens
- Center for Immunity and Immunotherapies, Seattle Children's Research Institute Arthritis Foundation, Seattle, WA, USA
| | - P M Gaffney
- Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - J B Harley
- 1] Division of Rheumatology and the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA [2] US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA
| | - C D Langefeld
- Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - C Fesel
- Instituto Gulbenkian de Ciência, Oeiras, Portugal
| |
Collapse
|
5
|
Kariuki SN, Ghodke-Puranik Y, Dorschner JM, Chrabot BS, Kelly JA, Tsao BP, Kimberly RP, Alarcón-Riquelme ME, Jacob CO, Criswell LA, Sivils KL, Langefeld CD, Harley JB, Skol AD, Niewold TB. Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun 2014; 16:15-23. [PMID: 25338677 PMCID: PMC4305028 DOI: 10.1038/gene.2014.57] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Revised: 09/10/2014] [Accepted: 09/11/2014] [Indexed: 12/13/2022]
Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder characterized by inflammation of multiple organ systems and dysregulated interferon responses. SLE is both genetically and phenotypically heterogeneous, greatly reducing the power of case-control studies in SLE. Elevated circulating interferon alpha (IFN-α) is a stable, heritable trait in SLE, which has been implicated in primary disease pathogenesis. 40–50% of patients have high IFN-α, and high levels correspond with clinical differences. To study genetic heterogeneity in SLE, we performed a case-case study comparing patients with high vs. low IFN-α in over 1550 SLE cases, including GWAS and replication cohorts. In meta-analysis, the top associations in European ancestry were PRKG1 rs7897633 (PMeta=2.75 × 10−8) and PNP rs1049564 (PMeta=1.24 × 10−7). We also found evidence for cross-ancestral background associations with the ANKRD44 and PLEKHF2 loci. These loci have not been previously identified in case-control SLE genetic studies. Bioinformatic analyses implicated these loci functionally in dendritic cells and natural killer cells, both of which are involved in IFN-α production in SLE. As case-control studies of heterogeneous diseases reach a limit of feasibility with respect to subject number and detectable effect size, the study of informative pathogenic subphenotypes becomes an attractive strategy for genetic discovery in complex disease.
Collapse
Affiliation(s)
- S N Kariuki
- Department of Human Genetics, University of Chicago, Chicago, IL, USA
| | - Y Ghodke-Puranik
- Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
| | - J M Dorschner
- Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
| | - B S Chrabot
- Gwen Knapp Center for Lupus Research, University of Chicago, Chicago, IL, USA
| | - J A Kelly
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - B P Tsao
- Department of Medicine, University of California, Los Angeles, CA, USA
| | - R P Kimberly
- Department of Medicine, University of Alabama, Birmingham, AL, USA
| | - M E Alarcón-Riquelme
- 1] Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA [2] GENYO Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain
| | - C O Jacob
- Department of Medicine, University of Southern California, Los Angeles, CA, USA
| | - L A Criswell
- Rosalind Russell/Ephraim P Engleman Rheumatology Research Center, University of California, San Francisco, CA, USA
| | - K L Sivils
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - C D Langefeld
- Department of Biostatistical Sciences, Wake Forest University, Winston-Salem, NC, USA
| | - J B Harley
- Cincinnati Children's Hospital Medical Center and Cincinnati VA Medical Center, Cincinnati, OH, USA
| | - A D Skol
- Department of Human Genetics, University of Chicago, Chicago, IL, USA
| | - T B Niewold
- Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
6
|
Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S, Block JA, Scanzello C, Sequeira W. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus 2014; 23:881-8. [PMID: 24786785 DOI: 10.1177/0961203314530793] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Accepted: 03/14/2014] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-alpha (IFN-α), and free light chains (FLCs: lambda, kappa) have all been noted to be of importance in systemic lupus erythematosus (SLE). Herein, we quantified and explored the relationship between these inflammatory mediators and disease activity in SLE; and stratified by their current anti-dsDNA antibody status. METHODS Seventy-seven SLE patients underwent assessment of disease activity using the SLE disease activity index (SLEDAI). Serum FLC (lambda, kappa, and total), IL-6, IL-10, and IFN-α were quantified. Demographics of disease characteristics were determined by chart reviews. Statistical analyses included Mann-Whitney test, chi square, and linear regression analyses. RESULTS Mean (SD) age of the patients was 44.9 ± 12.7 years; SLEDAI (mean ± SD) was 3.4 ± 4.0. Serum lambda FLC levels had a moderate correlation (r = 0.46 with physician global assessment, 0.44 with SLEDAI) and the strongest correlation with disease activity as compared with other inflammatory mediators including current dsDNA antibody status. After adjusting for prednisone use, the correlation of lambda FLC with PGA (r = 0.48) and SLEDAI (r = 0.52) was better than of current dsDNA antibody status with PGA (r = 0.33) and adjusted SLEDAI (r = 0.24), respectively. IL-10 and IFN-α activity did not correlate with disease activity. Serum FLC and IL-6 levels could differentiate between active and inactive SLE patients. Serum lambda FLC and IL-6 levels differed significantly among patients with and without current dsDNA antibodies. Serum lambda FLC levels accounted for 31% of variance in SLEDAI scores. CONCLUSION Serum FLC and IL-6 are potentially useful biomarkers of disease activity in SLE. Further studies, with larger study sample and longitudinal design, are indicated.
Collapse
Affiliation(s)
- M Jolly
- Rush University Medical Center, Section of Rheumatology, Chicago, IL, USA
| | - S Francis
- Central Dupage Hospital, Section of Rheumatology, Winfield, IL, USA
| | - R Aggarwal
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - R A Mikolaitis
- Rush University Medical Center, Section of Rheumatology, Chicago, IL, USA
| | | | - S Chubinskaya
- Rush University Medical Center, Section of Rheumatology, Chicago, IL, USA
| | - J A Block
- Rush University Medical Center, Section of Rheumatology, Chicago, IL, USA
| | - C Scanzello
- Rush University Medical Center, Section of Rheumatology, Chicago, IL, USA
| | - W Sequeira
- Rush University Medical Center, Section of Rheumatology, Chicago, IL, USA
| |
Collapse
|
7
|
Fließer EE, Korsten P, Koziolek MJ, Niewold TB, Patschan D, Müller GA, Patschan SA. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Lupus 2013; 22:1523-5. [DOI: 10.1177/0961203313504145] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We report the case of a 19-year-old woman with progressive proliferative lupus nephritis (LN) class III after induction and maintenance therapy with mycophenolate mofetil (MMF). Despite a satisfying clinical improvement proteinuria progressed under this medication. We treated the patient with additional belimumab after discussing other options. Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.
Collapse
Affiliation(s)
- EE Fließer
- Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany
| | - P Korsten
- Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany
| | - MJ Koziolek
- Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany
| | - TB Niewold
- Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, USA
| | - D Patschan
- Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany
| | - GA Müller
- Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany
| | - SA Patschan
- Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany
| |
Collapse
|
8
|
Chrabot B, Kariuki SN, Zervou M, Feng X, Arrington J, Jolly M, Boumpas DT, Reder AT, Goulielmos GN, Niewold TB. THU0026 Genetic Variation Near IRF8 is Associated with Serologic and Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Ko K, Koldobskaya Y, Rosenzweig E, Niewold TB. FRI0263 Activation of the interferon pathway is dependent upon autoantibodies in african american sle patients, but not in european-american sle patients. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Jensen MA, Patterson KC, Kumar AA, Kumabe M, Franek BS, Niewold TB. Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. Arthritis Res Ther 2012. [PMCID: PMC3467540 DOI: 10.1186/ar3997] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
11
|
Deng Y, Zhao J, Sakurai D, Kaufman KM, Edberg JC, Kimberly RP, Kamen DL, Gilkeson GS, Jacob CO, Scofield RH, Langefeld CD, Kelly JA, Alarcón-Riquelme ME, Harley JB, Vyse TJ, Freedman BI, Gaffney PM, Sivils KM, James JA, Niewold TB, Cantor RM, Chen W, Hahn BH, Brown EE, Tsao BP. MicroRNA-3148 modulates differential gene expression of the SLE-associated TLR7 variant. Arthritis Res Ther 2012. [PMCID: PMC3467482 DOI: 10.1186/ar3939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- Y Deng
- University of California, Los Angeles, CA, USA
| | - J Zhao
- University of California, Los Angeles, CA, USA
| | - D Sakurai
- University of California, Los Angeles, CA, USA
| | - KM Kaufman
- Center for Autoimmune Genomics & Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA,US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA
| | - JC Edberg
- University of Alabama at Birmingham, Birmingham, AL, USA
| | - RP Kimberly
- University of Alabama at Birmingham, Birmingham, AL, USA
| | - DL Kamen
- Medical University of South Carolina, Charleston, SC, USA
| | - GS Gilkeson
- Medical University of South Carolina, Charleston, SC, USA
| | - CO Jacob
- Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - RH Scofield
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA,University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA,US Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA
| | - CD Langefeld
- Wake Forest University Health Sciences, Wake Forest, NC, USA
| | - JA Kelly
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | | | - JB Harley
- Center for Autoimmune Genomics & Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA,US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA
| | | | - BI Freedman
- Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - PM Gaffney
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - KM Sivils
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - JA James
- Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA,University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
| | - TB Niewold
- Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, IL, USA
| | - RM Cantor
- University of California, Los Angeles, CA, USA
| | - W Chen
- University of California, Los Angeles, CA, USA
| | - BH Hahn
- University of California, Los Angeles, CA, USA
| | | | - BP Tsao
- University of California, Los Angeles, CA, USA
| |
Collapse
|
12
|
Eliopoulos E, Zervou MI, Andreou A, Dimopoulou K, Cosmidis N, Voloudakis G, Mysirlaki H, Vazgiourakis V, Sidiropoulos P, Niewold TB, Boumpas DT, Goulielmos GN. Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete. Lupus 2011; 20:501-6. [PMID: 21543514 PMCID: PMC3312778 DOI: 10.1177/0961203310392423] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Autoimmune diseases affect approximately 5% of the population, but much work remains to define the genetic risk factors and pathogenic mechanisms underlying these conditions. There is accumulating evidence that common genetic factors might predispose to multiple autoimmune disorders. Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are complex autoimmune disorders with multiple susceptibility genes. The functional R620W (C1858T) polymorphism of the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene, a member of the PTPs that negatively regulate T-cell activation, has been recently associated with susceptibility to various autoimmune diseases. The aim of this study was to assess whether the C1858T polymorphism of PTPN22 also confers increased risk for SLE and RA in the genetically homogeneous population of Crete. It was found that the minor T allele of the PTPN22 C1858T SNP was more common in SLE patients than in control individuals (odds ratio [OR] = 1.91, 95% confidence interval [CI] = 1.11 to 3.9, p = 0.017). No significant difference was observed in the frequency of this allele when RA patients were compared with controls (OR = 1.14, 95% CI = 0.65 to 1.9, p = 0.64). Although the PTPN22 1858 T allele is found at decreased frequency in Southern Europe, including Crete, an association was found between this allele and SLE in the population studied.
Collapse
Affiliation(s)
- E Eliopoulos
- Laboratory of Genetics, Department of Agricultural Biotechnology, Agricultural University of Athens, Greece
| | - MI Zervou
- Department of Internal Medicine, Medical School of Crete, University of Crete, Heraklion, Greece
| | - A Andreou
- Laboratory of Genetics, Department of Agricultural Biotechnology, Agricultural University of Athens, Greece
| | - K Dimopoulou
- Laboratory of Genetics, Department of Agricultural Biotechnology, Agricultural University of Athens, Greece
| | - N Cosmidis
- Laboratory of Genetics, Department of Agricultural Biotechnology, Agricultural University of Athens, Greece
| | - G Voloudakis
- Laboratory of Molecular Medicine and Human Genetics, Medical School of Crete, University of Crete, Heraklion, Greece
| | - H Mysirlaki
- Department of Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece
| | - V Vazgiourakis
- Laboratory of Molecular Medicine and Human Genetics, Medical School of Crete, University of Crete, Heraklion, Greece
| | - P Sidiropoulos
- Department of Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece
| | - TB Niewold
- Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, USA
| | - DT Boumpas
- Laboratory of Molecular Medicine and Human Genetics, Medical School of Crete, University of Crete, Heraklion, Greece
- Department of Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece
| | - GN Goulielmos
- Laboratory of Molecular Medicine and Human Genetics, Medical School of Crete, University of Crete, Heraklion, Greece
| |
Collapse
|
13
|
Franek BS, Kariuki SN, Arrington J, Mikolaitis RA, Jolly M, Utset TO, Zervou M, Boumpas DT, Goulielmos G, Niewold TB. IRF8 allele associated with susceptibility to multiple sclerosis is associated with serum interferon and serologic profile in systemic lupus erythematosus. Ann Rheum Dis 2011. [DOI: 10.1136/ard.2010.149096.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, Jolly M, Utset TO, Niewold TB. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2010. [DOI: 10.1136/ard.2010.129619n] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun 2009; 10:487-94. [PMID: 19339987 DOI: 10.1038/gene.2009.15] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Osteopontin (OPN) is a multifunctional cytokine involved in long bone remodeling and immune system signaling. Additionally, OPN is critical for interferon-alpha (IFN-alpha) production in murine plasmacytoid dendritic cells. We have previously shown that IFN-alpha is a heritable risk factor for systemic lupus erythematosus (SLE). Genetic variants of OPN have been associated with SLE susceptibility, and one study suggests that this association is particular to men. In this study, the 3' UTR SLE-risk variant of OPN (rs9138C) was associated with higher serum OPN and IFN-alpha in men (P=0.0062 and P=0.0087, respectively). In women, the association between rs9138 C and higher serum OPN and IFN-alpha was restricted to younger subjects, and risk allele carriers showed a strong age-related genetic effect of rs9138 genotype on both serum OPN and IFN-alpha (P<0.0001). In African-American subjects, the 5' region single nucleotide polymorphisms, rs11730582 and rs28357094, were associated with anti-RNP antibodies (odds ratio (OR)=2.9, P=0.0038 and OR=3.9, P=0.021, respectively). Thus, we demonstrate two distinct genetic influences of OPN on serum protein traits in SLE patients, which correspond to previously reported SLE-risk variants. This study provides a biologic relevance for OPN variants at the protein level, and suggests an influence of this gene on the IFN-alpha pathway in SLE.
Collapse
Affiliation(s)
- S N Kariuki
- Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA
| | | | | | | | | | | |
Collapse
|
16
|
Cantaert T, De Rycke L, Mavragani CP, Wijbrandts CA, Niewold TB, Niers T, Vandooren B, Veys EM, Richel D, Tak PP, Crow MK, Baeten D. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis 2008; 68:1022-9. [PMID: 18625621 DOI: 10.1136/ard.2008.093724] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Type I interferons and apoptotic particles contribute to antinuclear autoimmunity in experimental models. This study assessed whether similar mechanisms contribute to break peripheral B-cell tolerance in humans by studying the induction of antinuclear antibodies by tumour necrosis factor blockade in spondyloarthritis. METHODS 40 spondyloarthritis patients treated with infliximab or etanercept and 20 renal cell carcinoma patients treated with sorafenib were studied. Serum antinucleosome IgM and nucleosomes were measured by ELISA. Type I interferon serum activity was measured using a functional reporter cell assay. Synovial apoptosis was assessed by terminal transferase nick end-labelling (TUNEL) assay and anti-active caspase-3 immunostaining. Complement was measured by nephelometry. RESULTS Despite a similar clinical improvement and reduction of synovial inflammation, antinucleosome IgM were induced by infliximab but not etanercept. This induction did not correlate with type I interferon activity, which was transiently downmodulated by infliximab but persistently upregulated by etanercept. In contrast, antinucleosome IgM levels did correlate with serum nucleosome levels, which were significantly upregulated by infliximab but not by etanercept treatment. This increase in serum nucleosome levels was not directly related to massive cell death, but rather to a decrease of complement 3 and 4 serum levels during infliximab treatment. CONCLUSION Infliximab and etanercept have a differential effect on both type I interferon activity and nucleosome levels. Only elevated serum nucleosomes relate to the induction of antinucleosome antibodies after infliximab treatment.
Collapse
Affiliation(s)
- T Cantaert
- Academic Medical Center/University of Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Interferon alpha (IFN-alpha) levels are elevated in many patients with systemic lupus erythematosus (SLE); however it is not known whether high serum IFN-alpha activity is a cause or a result of the disease. We studied 266 SLE patients and 405 of their healthy relatives, and frequently found high serum IFN-alpha activity in both patients and healthy relatives as compared to healthy unrelated individuals. High IFN-alpha activity was clustered in specific families in both SLE patients and their healthy first-degree relatives, suggesting a heritable trait. Heritability was also supported by quantitative familial correlation of IFN-alpha activity, concordance in affected sib pairs and frequent transmission of the high IFN-alpha activity trait from parents to offspring. Autoantibodies to RNA-binding proteins and double-stranded DNA were associated with high IFN-alpha activity in SLE patients; however these autoantibodies were very uncommon in healthy family members and did not explain the observed familial correlations. The frequency of high IFN-alpha activity was similar across all studied ethnic backgrounds. These data suggest that high serum IFN-alpha activity is a complex heritable trait, which plays a primary role in SLE pathogenesis.
Collapse
Affiliation(s)
- T B Niewold
- Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA.
| | | | | | | | | |
Collapse
|
18
|
Abstract
Rheumatoid arthritis is both common and chronic, with significant consequences for multiple organ systems. Better understanding of its pathophysiology has led to the development of targeted therapies that have dramatically improved outcomes. The key to therapeutic success lies in identifying individuals who will have severe destructive disease as early as possible, so that effective treatment can be initiated before irreversible damage occurs. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing is particularly useful in the diagnosis of rheumatoid arthritis, with high specificity, presence early in the disease process, and ability to identify patients who are likely to have severe disease and irreversible damage. However, its sensitivity is low, and a negative result does not exclude disease. Anti-CCP antibodies have not been found at a significant frequency in other diseases to date, and are more specific than rheumatoid factor for detecting rheumatoid arthritis. We discuss anti-CCP antibody testing in rheumatoid arthritis, with an emphasis on diagnostic performance, prognostic capability, and relevance to pathogenesis and new treatment paradigms in rheumatoid arthritis.
Collapse
Affiliation(s)
- T B Niewold
- Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021, USA.
| | | | | |
Collapse
|
19
|
Abstract
We report the case of an adult who developed severe post-streptococcal reactive arthritis (PSRA) and poststreptococcal glomerulonephritis (PSGN) after a subclinical streptococcal infection. Antistreptococcal antibody titres, renal biopsy and the clinical course confirmed the diagnosis. Coincidence of PSRA and PSGN is rare in the adult population and the potential for misdiagnosis exists, particularly when prior streptococcal infection is not apparent. The clinical manifestations of poststreptococcal syndromes are highly variable, and the diagnosis of concomitant PSRA and PSGN should be considered when patients present with glomerulonephritis and inflammatory arthritis. Factors from both the host and the pathogen are probably important in determining disease expression in poststreptococcal syndromes.
Collapse
Affiliation(s)
- T B Niewold
- Mayo Clinic, Rochester, Minnesota 55905, USA
| | | |
Collapse
|
20
|
Abstract
The methyl-accepting chemotaxis protein, McpB, is the sole receptor mediating asparagine chemotaxis in Bacillus subtilis. In this study, we show that wild-type B. subtilis cells contain approximately 2,000 copies of McpB per cell, that these receptors are localized polarly, and that titration of only a few receptors is sufficient to generate a detectable behavioural response. In contrast to the wild type, a cheB mutant was incapable of tumbling in response to decreasing concentrations of asparagine, but the cheB mutant was able to accumulate to low concentrations of asparagine in the capillary assay, as observed previously in response to azetidine-2-carboxylate. Furthermore, net demethylation of McpB is logarithmically dependent on asparagine concentration, with half-maximal demethylation of McpB occurring when only 3% of the receptors are titrated. Because the corresponding methanol production is exponentially dependent on attractant concentration, net methylation changes and increased turnover of methyl groups must occur on McpB at high concentrations of asparagine. Together, the data support the hypothesis that methylation changes occur on asparagine-bound McpB to enhance the dynamic range of the receptor complex and to enable the cell to respond to a negative stimulus, such as removal of asparagine.
Collapse
Affiliation(s)
- J R Kirby
- Department of Biochemistry, University of Illinois, Urbana 61801, USA
| | | | | | | |
Collapse
|